Iovance Biotherapeutics, Inc. (LON:0JDK)

Iovance Biotherapeutics Ratios and Metrics

Market cap in millions GBP. Fiscal year is January - December.

Fiscal Year	Current	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Feb 20, 2025	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	1,394	1,633	837	2,212	4,985	2,637
Market Cap Growth	130.17%	95.13%	-62.16%	-55.63%	89.02%	208.38%
Enterprise Value	1,142	1,412	605	1,840	4,470	2,375
Last Close Price	4.57	6.40	5.12	14.31	32.95	18.78
PS Ratio	31.37	1749.89	-	-	-	-
PB Ratio	3.68	3.56	2.02	4.82	10.37	11.68
P/TBV Ratio	6.11	5.86	2.02	4.82	10.37	11.68
EV/Sales Ratio	15.88	1512.80	-	-	-	-
Debt / Equity Ratio	0.10	0.13	0.17	0.12	0.08	0.04
Asset Turnover	0.10	0.00	-	-	-	-
Quick Ratio	3.84	2.54	5.16	5.65	11.47	7.86
Current Ratio	4.22	2.79	5.24	5.69	11.59	8.10
Return on Equity (ROE)	-56.65%	-81.91%	-70.61%	-53.55%	-54.34%	-51.64%
Return on Assets (ROA)	-29.15%	-39.86%	-34.59%	-27.71%	-29.41%	-31.33%
Return on Capital (ROIC)	-33.47%	-46.22%	-39.01%	-30.57%	-32.14%	-33.29%
Earnings Yield	-21.95%	-21.34%	-39.25%	-11.43%	-3.81%	-5.66%
FCF Yield	-20.03%	-18.46%	-31.05%	-8.86%	-3.70%	-4.75%
Buyback Yield / Dilution	-30.80%	-47.64%	-3.82%	-10.92%	-11.23%	-27.82%
Total Shareholder Return	-30.80%	-47.64%	-3.82%	-10.92%	-11.23%	-27.82%

Source: S&P Capital IQ. Standard template. Financial Sources.